Inovio Pharmaceuticals, Inc. (NASDAQ: INO)

Inovio Pharmaceuticals, Inc. (INO), a clinical-stage biotechnology company, is dedicated to the development and commercialization of DNA medicines for the treatment of diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The company's platform leverages the power of in vivo protein production, utilizing optimized design and delivery of DNA medicines to teach the body to manufacture its own disease-fighting tools.

Inovio Pharmaceuticals' DNA medicines platform consists of DNA plasmids and its proprietary CELLECTRA delivery technology. The DNA plasmids are designed to express specific proteins that elicit an immune response, and the CELLECTRA devices use electroporation to deliver the DNA plasmids into cells. This platform provides a competitive advantage in the development of DNA medicines for the treatment of diseases associated with HPV, cancer, and infectious diseases. The CELLECTRA devices have been designed to optimize delivery of DNA medicine candidates, depending on the target disease.

The company's lead candidate, INO-3107, is a DNA medicine designed to treat recurrent respiratory papillomatosis (RRP), a rare and debilitating disease caused by HPV infection. INO-3107 has demonstrated promising results in clinical trials, with 81.3% of patients experiencing a reduction in the number of surgical interventions in the year following treatment, and 28.1% of patients requiring no surgical intervention during or after treatment. Inovio plans to use the standard needle in its planned confirmatory trial and for delivery of the commercial product, should it be approved.

In addition to INO-3107, Inovio Pharmaceuticals is developing several other DNA medicine candidates. These include INO-3112 for the treatment of HPV-related oropharyngeal squamous cell carcinoma (OPSCC), and VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions (HSIL). The company has also partnered with Coherus BioSciences, Inc. to evaluate the combination of INO-3112 and LOQTORZI (toripalimab-tpzi) as a potential treatment for patients with locoregionally advanced, high-risk, HPV16/18 positive oropharyngeal squamous cell carcinoma.

Inovio Pharmaceuticals has received several designations from the U.S. Food and Drug Administration (FDA), including Orphan Drug Designation and Breakthrough Therapy Designation for its lead candidate, INO-3107. These designations underscore the potential of Inovio's DNA medicines to address unmet medical needs.

The company's commercialization strategy includes developing and commercializing products both on its own and through its collaborators and licensees. Inovio Pharmaceuticals intends to develop and commercialize products in well-defined specialty markets, such as HPV-related diseases, infectious diseases, and cancer. The company plans to rely on strategic marketing and distribution alliances to commercialize its products.

Inovio Pharmaceuticals has a strong intellectual property portfolio, with approximately 120 issued U.S. patents and approximately 100 U.S. patent applications, as well as approximately 1,100 issued foreign counterpart patents and approximately 800 counterpart foreign patent applications. This robust patent portfolio includes patents and patent applications directed to treatment of RRP, GBM, and other diseases.